Publications [#132233] of James M Provenzale

Papers Published

1. DA Reardon, JA Quinn, JJ Vredenburgh, S Gururangan, AH Friedman, A Desjardins, S Sathornsumetee, JE Herndon, JM Dowell, RE McLendon, JM Provenzale, JH Sampson, RP Smith, AJ Swaisland, JS Ochs, P Lyons, S Tourt-Uhlig, DD Bigner, HS Friedman, JN Rich, Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma., Clinical cancer research : an official journal of the American Association for Cancer Research, United States, vol. 12 no. 3 Pt 1 (February, 2006), pp. 860-8, ISSN 1078-0432
   (last updated on 2007/02/06)

   Abstract:
   PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent malignant glioma. PATIENTS AND METHODS: Gefitinib and sirolimus were administered on a continuous daily dosing schedule at dose levels that were escalated in successive cohorts of malignant glioma patients at any recurrence who were stratified based on concurrent use of CYP3A-inducing anticonvulsants [enzyme-inducing antiepileptic drugs, (EIAED)]. Pharmacokinetic and archival tumor biomarker data were also assessed. RESULTS: Thirty-four patients with progressive disease after prior radiation therapy and chemotherapy were enrolled, including 29 (85%) with glioblastoma multiforme and 5 (15%) with anaplastic glioma. The MTD was 500 mg of gefitinib plus 5 mg of sirolimus for patients not on EIAEDs and 1,000 mg of gefitinib plus 10 mg of sirolimus for patients on EIAEDs. DLTs included mucositis, diarrhea, rash, thrombocytopenia, and hypertriglyceridemia. Gefitinib exposure was not affected by sirolimus administration but was significantly lowered by concurrent EIAED use. Two patients (6%) achieved a partial radiographic response, and 13 patients (38%) achieved stable disease. CONCLUSION: We show that gefitinib plus sirolimus can be safely coadministered on a continuous, daily dosing schedule, and established the recommended dose level of these agents in combination for future phase 2 clinical trials.

   Keywords:
   Administration, Oral • Adult • Aged • Antineoplastic Combined Chemotherapy Protocols • Dose-Response Relationship, Drug • Drug Administration Schedule • Female • Glioma • Humans • Male • Middle Aged • Quinazolines • Recurrence • Sirolimus • Treatment Outcome • Tumor Markers, Biological • administration & dosage* • analysis • drug therapy* • therapeutic use*